Johan de Ruiter has many years of experience in the global medical technology and healthcare industry. Until 2007 he served on the executive board of a medium-sized company in orthopedics, diabetes and vascular surgery from the USA (Aircast LLC). Together with his colleagues he sold the company, whose main investor was Tailwind Capital Partners, to DJO Global in 2006.
Prior to that, Johan de Ruiter served as Executive Vice President Dialysis International at Fresenius AG, where he was responsible for all dialysis activities outside Germany and was the initiator and founder of Fresenius Medical Care AG with an IPO at the stock exchanges in Frankfurt and New York. He then founded a company which operates medical laboratories which is now part of Amedes Holding AG.
He is Chairman of Quanta Fluid Solutions in UK (a disruptive hemodialysis technology), founded the Auxilium group (rehabilitation, home care, orthopedics, surgical supplies), which is the largest provider in its market in Germany. b-to-v is a founding investor in both companies. Moreover, he is a non-executive board member at GNA Biosolutions (also backed by btov) and the owner of Sanitaetshaus Achim Kunze GmbH.
In 1980 Johan de Ruiter started his career with the Dade Diagnostics division of American Hospital Supply (Baxter resp. Siemens healthcare). Later he worked as European Product Manager at Abbott Diagnostics and then seven years at A. T. Kearney Management Consultants. In addition, since 2001 Johan de Ruiter is on the board of CHT Beitlich/Bezema Group (Chairman), a chemical company from Tuebingen, Germany/Montlingen, Switzerland.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.